Zhentai Biotech secures Pre-A round to advance industrialization of Citrate and Collagen for aesthetic medicine

Nov 12, 2025 16:07 CST Updated Nov 13, 09:43

Recently, Guangdong Zhentai Biotechnology, a company focused on medical aesthetic materials, has secured its Pre-A round of financing from Kunshan High-Tech Group.

The proceeds from this round will be used primarily to advance the R&D of citric acid materials, collagen, and their formulated products, and to accelerate the industrialization of core technologies like recombinant collagen.

Zhentai Biotech is a company focused on the research, development, and commercialization of materials for aesthetic medicine. Incubated by the Huangpu Institute of Materials of the Chinese Academy of Sciences, the company was founded in October 2023 by Huang Jianguo, a serial entrepreneur with extensive experience in biomaterials and the beauty industry. Merely two months after its inception, Zhentai Biotech secured tens of millions of RMB in its Angel round of financing. The investment consortium included the Guangdong-Hong Kong-Macao Greater Bay Area Huangpu Institute of Materials, leading institutional investors, and senior executives from listed companies.

Its R&D pipeline primarily comprises: rare ginsenosides, biodegradable polymers (citric acid/malic acid polyester, PLLA, PCL, etc.), recombinant ECM-fusion protein, and animal/recombinant collagen.

On October 19, 2025, the opening ceremony for the office of Zhentai Biotech's Kunshan facility was successfully held, marking a new phase in the company's strategic expansion. Looking ahead, Zhentai Biotech will establish a modern, intelligent production base at the Kunshan site.